Intranasal steroids inhibit seasonal increases in ragweed-specific immunoglobulin IE antibodies

Research output: Contribution to journalArticle

Abstract

We performed two seasonal studies to evaluate the effect of continuous treatment with intranasal steroids, beginning approximately 1 week before the apperance of ragweed pollen, on the level of ragweed-specific IgE antibodies in serum. In both studies the control groups showed the anticipated rise in ragweed-specific IgE antibodies after the ragweed season. In the first study, employing aqueous beclomethasone dipropionate (168 μg twice daily), no rise occurred in serum ragweed IgE after seasonal exposure and the level actually decreased in eight of 12 treated subjects. In the second study, with triamcinolone acetonide (220 μg twice daily), the expected rise in ragweed IgE antibody was also reduced, although less dramatically, probably as a result of the lower potency of the dose delivered. Our studies not only support the benefits of intranasal steroids in the treatment of seasonal allergic rhinitis but also suggest that specific IgE production may be down-regulated by their continuous use, which may alter the subsequent clinical course of the disease.

Original languageEnglish (US)
Pages (from-to)717-721
Number of pages5
JournalThe Journal of Allergy and Clinical Immunology
Volume92
Issue number5
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Ambrosia
Immunoglobulin E
Immunoglobulins
Steroids
Antibodies
Beclomethasone
Triamcinolone Acetonide
Seasonal Allergic Rhinitis
Serum
Control Groups

Keywords

  • allergic rhinitis
  • beclomethasone
  • intranasal steroids
  • Ragweed
  • serum ragweed IgE
  • triamcinolone

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

@article{b4ff59ae6f5a48f691e12ec40137107b,
title = "Intranasal steroids inhibit seasonal increases in ragweed-specific immunoglobulin IE antibodies",
abstract = "We performed two seasonal studies to evaluate the effect of continuous treatment with intranasal steroids, beginning approximately 1 week before the apperance of ragweed pollen, on the level of ragweed-specific IgE antibodies in serum. In both studies the control groups showed the anticipated rise in ragweed-specific IgE antibodies after the ragweed season. In the first study, employing aqueous beclomethasone dipropionate (168 μg twice daily), no rise occurred in serum ragweed IgE after seasonal exposure and the level actually decreased in eight of 12 treated subjects. In the second study, with triamcinolone acetonide (220 μg twice daily), the expected rise in ragweed IgE antibody was also reduced, although less dramatically, probably as a result of the lower potency of the dose delivered. Our studies not only support the benefits of intranasal steroids in the treatment of seasonal allergic rhinitis but also suggest that specific IgE production may be down-regulated by their continuous use, which may alter the subsequent clinical course of the disease.",
keywords = "allergic rhinitis, beclomethasone, intranasal steroids, Ragweed, serum ragweed IgE, triamcinolone",
author = "Naclerio, {Robert M.} and Adkinson, {N Franklin} and Creticos, {Peter Socrates} and Baroody, {Fuad M.} and Hamilton, {Robert G} and Norman, {Philip S.}",
year = "1993",
doi = "10.1016/0091-6749(93)90015-8",
language = "English (US)",
volume = "92",
pages = "717--721",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Intranasal steroids inhibit seasonal increases in ragweed-specific immunoglobulin IE antibodies

AU - Naclerio, Robert M.

AU - Adkinson, N Franklin

AU - Creticos, Peter Socrates

AU - Baroody, Fuad M.

AU - Hamilton, Robert G

AU - Norman, Philip S.

PY - 1993

Y1 - 1993

N2 - We performed two seasonal studies to evaluate the effect of continuous treatment with intranasal steroids, beginning approximately 1 week before the apperance of ragweed pollen, on the level of ragweed-specific IgE antibodies in serum. In both studies the control groups showed the anticipated rise in ragweed-specific IgE antibodies after the ragweed season. In the first study, employing aqueous beclomethasone dipropionate (168 μg twice daily), no rise occurred in serum ragweed IgE after seasonal exposure and the level actually decreased in eight of 12 treated subjects. In the second study, with triamcinolone acetonide (220 μg twice daily), the expected rise in ragweed IgE antibody was also reduced, although less dramatically, probably as a result of the lower potency of the dose delivered. Our studies not only support the benefits of intranasal steroids in the treatment of seasonal allergic rhinitis but also suggest that specific IgE production may be down-regulated by their continuous use, which may alter the subsequent clinical course of the disease.

AB - We performed two seasonal studies to evaluate the effect of continuous treatment with intranasal steroids, beginning approximately 1 week before the apperance of ragweed pollen, on the level of ragweed-specific IgE antibodies in serum. In both studies the control groups showed the anticipated rise in ragweed-specific IgE antibodies after the ragweed season. In the first study, employing aqueous beclomethasone dipropionate (168 μg twice daily), no rise occurred in serum ragweed IgE after seasonal exposure and the level actually decreased in eight of 12 treated subjects. In the second study, with triamcinolone acetonide (220 μg twice daily), the expected rise in ragweed IgE antibody was also reduced, although less dramatically, probably as a result of the lower potency of the dose delivered. Our studies not only support the benefits of intranasal steroids in the treatment of seasonal allergic rhinitis but also suggest that specific IgE production may be down-regulated by their continuous use, which may alter the subsequent clinical course of the disease.

KW - allergic rhinitis

KW - beclomethasone

KW - intranasal steroids

KW - Ragweed

KW - serum ragweed IgE

KW - triamcinolone

UR - http://www.scopus.com/inward/record.url?scp=0027436017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027436017&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(93)90015-8

DO - 10.1016/0091-6749(93)90015-8

M3 - Article

C2 - 8227863

AN - SCOPUS:0027436017

VL - 92

SP - 717

EP - 721

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5

ER -